Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial

Solomon, Scott; Claggett, Brian; Desai, Akshay; Packer, Milton; Zile, Michael; Swedberg, Karl; Rouleau, Jean; Shi, Victor; Starling, Randall; Kozan, Omer; Dukat, Andrej; Lefkowitz, Martin; McMurray, John

doi:10.1161/circheartfailure.115.002744

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial

Solomon S. D., Claggett B., Desai A. S., Packer M., Zile M., Swedberg K., ...More

CIRCULATION-HEART FAILURE, vol.9, no.3, 2016 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 9 Issue: 3
Publication Date: 2016
Doi Number: 10.1161/circheartfailure.115.002744
Journal Name: CIRCULATION-HEART FAILURE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Keywords: heart, heart failure, humans, mineralocorticoid receptor antagonists, neprilysin
Open Archive Collection: AVESIS Open Access Collection
Dokuz Eylül University Affiliated: Yes

Abstract

Background The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril.